Literature DB >> 28239565

PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression.

Kim A Brogden1, Shireen Vali2, Taher Abbasi2.   

Abstract

Entities:  

Year:  2016        PMID： 28239565      PMCID： PMC5323246          DOI： 10.21037/tcr.2016.12.43

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  11 in total

1.  PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?

Authors:  Feriyl Bhaijee; Robert A Anders
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

Review 2.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

3.  CANCER IMMUNOLOGY. The "cancer immunogram".

Authors:  Christian U Blank; John B Haanen; Antoni Ribas; Ton N Schumacher
Journal:  Science       Date:  2016-05-06       Impact factor: 47.728

Review 4.  Programmed death-1 pathway in cancer and autoimmunity.

Authors:  Ariel Pedoeem; Inbar Azoulay-Alfaguter; Marianne Strazza; Gregg J Silverman; Adam Mor
Journal:  Clin Immunol       Date:  2014-04-26       Impact factor: 3.969

Review 5.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer.

Authors:  J Chen; C C Jiang; L Jin; X D Zhang
Journal:  Ann Oncol       Date:  2015-12-17       Impact factor: 32.976

6.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 7.  The PD-1 pathway in tolerance and autoimmunity.

Authors:  Loise M Francisco; Peter T Sage; Arlene H Sharpe
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

8.  Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Authors:  Curtis A Clark; Harshita B Gupta; Gangadhara Sareddy; Srilakshmi Pandeswara; Shunhua Lao; Bin Yuan; Justin M Drerup; Alvaro Padron; José Conejo-Garcia; Kruthi Murthy; Yang Liu; Mary Jo Turk; Kathrin Thedieck; Vincent Hurez; Rong Li; Ratna Vadlamudi; Tyler J Curiel
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

9.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

Review 10.  T-cell exhaustion in the tumor microenvironment.

Authors:  Y Jiang; Y Li; B Zhu
Journal:  Cell Death Dis       Date:  2015-06-18       Impact factor: 8.469
View more
  3 in total

1.  Producing Soluble Human Programmed Cell Death Protein-1: A Natural Supporter for CD4+T Cell Cytotoxicity and Tumor Cells Apoptosis.

Authors:  Samane Mohammadzadeh; Hossein Khanahmad; Nafiseh Esmaeil; Nahid Eskandari; Ilnaz Rahimmanesh; Abbas Rezaei; Alireza Andalib
Journal:  Iran J Biotechnol       Date:  2019-12-01       Impact factor: 1.671

Review 2.  Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).

Authors:  Enrique Espinosa; Ivan Márquez-Rodas; Ainara Soria; Alfonso Berrocal; Jose Luis Manzano; Maria Gonzalez-Cao; Salvador Martin-Algarra
Journal:  Ann Transl Med       Date:  2017-10

3.  Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.

Authors:  Xuhan Zhang; Lu Liu; Shiyong Zhou; Kuo Zhao; Zheng Song; Ge Hu; Tingting Zhang; Yang Li; Lihua Qiu; Lanfang Li; Zhengzi Qian; Bin Meng; Yi Pan; Xiubao Ren; Xianhuo Wang; Huilai Zhang; Kai Fu
Journal:  Hematol Oncol       Date:  2019-05-30       Impact factor: 5.271
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.